Navigation Links
Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR

About Cyclacel Pharmaceuticals, Inc.

Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The Company is currently evaluating seliciclib (CYC202), an orally-available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer. Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside analog, is in Phase I clinical trials for the treatment of solid and hematological cancers. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage.

About seliciclib

Seliciclib is an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits multiple enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been evaluated in approximately 250 patients, including patients with advanced NSCLC in which seliciclib was administered in combination with gemcitabine and cisplatin as first-line treatment and with docetaxel as second-line treatment. Seliciclib is currently being evaluated as a third-line treatment for Non-Small Cell Lung Cancer (NSCLC) in the Phase IIb, multi-center, randomized, double-blinded "APPRAISE" trial with the goal of generating a strong signal of activity in terms of Progression Free Survival. Cyclacel also intends to initiate a Phase II trial of seliciclib as a treatment for patients with nasopharyngeal cancer (NPC), a disease associated with Epstein-Barr Virus infection, in the second half of 2007.

About sapacitabine

Sapacitabine is an oral nucleoside analog prodrug that acts through a novel mechanism. The compound interferes with DNA synthesis by causing single-strand DNA breaks and induces arrest of the cell
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:7/31/2014)... De Pfizer Clinical Research Unit (PCRU) heeft ... van Japanse komaf voor medewerking aan klinisch onderzoek. De ... één van twee onderzoekseenheden van Pfizer , een ... door de ontdekking en ontwikkeling van nieuwe medicijnen. Om ... mannen en vrouwen van Japanse komaf – leeftijd 18 ...
(Date:7/30/2014)... , July 30, 2014  Cepheid (Nasdaq: ... group purchasing contract with Premier will end on ... Premier GPO will be able to continue their ... Baycare, HPA, MedAssets, Novation, and ROi, in addition ... directly with Cepheid. "Cepheid has always ...
(Date:7/30/2014)... 2014 The Board of Directors of ... evening expressed support for the "Pharmacists, Patient Care ... Pharmacy Practitioners (JCPP).  As a JCPP member, AMCP ... period to develop a scalable, viable and consistent ... "Pharmacists are fast becoming one of the most ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... Reportlinker.com announces that a new market ... Commercial Insight: Antihormonal Cancer ... generic sales erosion ... therapies are a class of drugs used ...
... NEW YORK, Nov. 8, 2010 Reportlinker.com ... is available in its catalogue: ... for optimizing growth in key regions and ... The flurry of recent ...
Cached Medicine Technology:Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 2Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 3Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 4Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 5Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 6Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 7Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 8Commercial Insight: Antihormonal Cancer Therapies - Leading Brands Strive to Minimize Generic Sales Erosion 9Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 2Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 3Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 4Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 5Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 6Opportunities in Emerging Pharma Markets: Strategies for Optimizing Growth in Key Regions and Therapeutic Areas 7
(Date:7/31/2014)... CITY, Mo. (PRWEB) July 31, 2014 ... of highly experienced, sub-specialty trained neurosurgeons at the ... of the Spine Program and director of spine surgery. ... in Richland, Wash. , “Dr. Upadhyaya has been recognized ... invasive and complex spine issues. His addition to the ...
(Date:7/31/2014)... Recognizing that today’s medical students are tomorrow’s ... announced today its student discount program. ... a healthcare-related field, as well as medical residents in ... the conference, scheduled for September 17-20, 2014 in San ... , “As a future Registered Dietitian, I’m excited ...
(Date:7/31/2014)... 2014 When it comes to aesthetics ... and improve. As such, Natalie Sharp's Pure Vitality ... for a new, more focused direction and to provide ... patients! , Pure Vitality Rx is Oyster Bay's premier ... wide variety of services primarily dedicated to women. Services ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
(Date:7/31/2014)... July 31, 2014 Sales in the organic ... to 2014, according to radio talk show host Sharon Kleyne, ... rapid growth since 1990. The US economy in the same ... Power of Water radio show, reported this information following a ... a worldwide manufacturer of organic and natural food products. ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 2Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 3Health News:Saint Luke’s Marion Bloch Neuroscience Institute welcomes Cheerag D. Upadhyaya, M.D., as director of Spine Program 4Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:Natalie Sharp's Pure Vitality Rx Upgrade - Partnership With Shangri-La Spa and Website Facelift! 2Health News:Women in military less likely to drink than civilian women 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 2Health News:Organic Food Industry Grew 12% in 2013-2014 Reports Sharon Kleyne Hour Power of Water Host 3
... Synovics,Pharmaceuticals, Inc. (OTC Bulletin Board: SYVC), a ... Gange, has been,appointed Principal Executive Officer of ... responsibility of overseeing all executive functions. Mr. ... of directors and is the Chief,Financial Officer ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today ... President, Tax. Mr. Laty had previously been the,Vice President, ... had,over eight years experience with a "Big 4" accounting ... Estate Investment Trusts. Mr. Laty is,a graduate of California ...
... do find 11 anti-seizure drugs heighten suicide risk, and ... 10 (HealthDay News) -- Anti-seizure drugs can cause ... warrant the government,s strongest warning label on them, a ... 20-member panel voted unanimously, with one abstention, to back ...
... of Mental Health estimates that in any given year, ... from some form of anxiety disorder, including debilitating conditions ... (PTSD). It is estimated that nearly 15 percent ... PTSD, underscoring the urgency to develop better treatment strategies ...
... trials, design may also mask risk of HIV drug resistance ... study questions whether vaginal microbicides being developed to help protect ... from the virus that causes AIDS. , The study, ... of the National Academy of Sciences , also shows that, ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
Cached Medicine News:Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 2Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 3Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 4Health News:Synovics Pharmaceuticals Announces the Appointment of Jyotindra Gange as Principal Executive Officer 5Health News:FDA Advisers Don't Back Epilepsy Drug Warnings 2Health News:Rutgers research identifies brain cells related to fear 2Health News:Rutgers research identifies brain cells related to fear 3Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3
... As a prophylaxis for deep vein ... effective combination of graduated sequential compression and ... thrombus formation by increasing venous ejection while ... VenaFlow System includes a pump with tube ...
... Full Transportability: Innovative design allows the ... in for therapy or when to ... Choose the prophylactic method to deliver ... both simultaneously. ,Automatic Garment Detection: Automatically ...
... boot specially lasted for fiberglass casts... ... sole for easy ambulation! ,The SlimLine ... last so it fits better than ... with our stretchable upper, a custom ...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: